Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Oksana Mokliatchouk"'
Autor:
Kunio Nakamura, Oksana Mokliatchouk, Douglas L. Arnold, Tarek A. Yousry, Ludwig Kappos, Nancy Richert, Katherine Ayling-Rouse, Catherine Miller, Elizabeth Fisher
Publikováno v:
Frontiers in Neurology, Vol 13 (2022)
ObjectiveIn the pivotal DEFINE and CONFIRM trials for dimethyl fumarate (DMF), patterns of brain volume changes were different, potentially due to low sample sizes and because MRIs were analyzed at two different reading centers. We evaluated effects
Externí odkaz:
https://doaj.org/article/3c3cf3c985ca4d5492c4c0c415468159
Autor:
Krupa Pandey, Kathryn Giles, Konstantin Balashov, Richard Macdonell, Jorg Windsheimer, Mikel Martinez, Ivan Bozin, Xiaotong Jiang, Jennifer Lyons, Oksana Mokliatchouk, Annette Okai
Publikováno v:
Tuesday, April 25.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa3b45d5287a1a6c22414b851c4094ee
https://doi.org/10.1212/wnl.0000000000201963
https://doi.org/10.1212/wnl.0000000000201963
Autor:
Kerstin Hellwig, David Rog, Christopher McGuigan, Maria Houtchens, Denise Bruen, Oksana Mokliatchouk, Filipe Branco, Seth Levin, Xiaochen Lin
Publikováno v:
Tuesday, April 25.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df9550ca59dcef7b75d14afbb739db55
https://doi.org/10.1212/wnl.0000000000203566
https://doi.org/10.1212/wnl.0000000000203566
Autor:
Xiaotong Jiang, Catherine Miller, Ralf Gold, Amit Bar-Or, Oksana Mokliatchouk, Douglas L. Arnold, Shivani Kapadia, Robert J. Fox, Jennifer L. Lyons, Ludwig Kappos
Publikováno v:
Multiple Sclerosis Journal. 28:801-816
Background: Dimethyl fumarate (DMF) demonstrated favorable benefit–risk in relapsing-remitting multiple sclerosis (RRMS) patients in phase-III DEFINE and CONFIRM trials, and ENDORSE extension. Objective: The main aim of this study is assessing DMF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55c119bf6b7c9ea168b09bc364b0a10b
https://doi.org/10.1177/13524585211037909
https://doi.org/10.1177/13524585211037909
Autor:
Patrick Vermersch, Matthew Scaramozza, Seth Levin, Raed Alroughani, Kumaran Deiva, Carlo Pozzilli, Jennifer Lyons, Oksana Mokliatchouk, Joe Pultz, Fatou N’Dure, Shifang Liu, Runda Badwan, Filipe Branco, Valencia Hood-Humphrey, Nathalie Franchimont, Jerome Hanna, Amir-Hadi Maghzi
Publikováno v:
JAMA network open. 5(9)
ImportanceWith few approved multiple sclerosis therapies in the pediatric population, there is a need for further approved treatment options. Limited data exist for dimethyl fumarate (DMF) treatment in pediatric-onset multiple sclerosis (POMS).Object
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a9da75e90d49bf0dd6287d866d95a5c
https://pubmed.ncbi.nlm.nih.gov/36169961
https://pubmed.ncbi.nlm.nih.gov/36169961
Autor:
Max Waschbusch, Lisa Rodriguez, Andreas Brueckner, Kerry Jo Lee, Xuefeng Li, Oksana Mokliatchouk, Lothar Tremmel, Shuai S. Yuan
Publikováno v:
Pharmaceutical medicine. 36(4)
In the last decade there has been a significant increase in the literature discussing the use of benefit-risk methods in medical product (including devices) development. Government agencies, medical product industry groups, academia, and collaborativ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c87f914caf490e6539ec19045037f36
https://pubmed.ncbi.nlm.nih.gov/35780471
https://pubmed.ncbi.nlm.nih.gov/35780471
BackgroundBlack/African-American participants are underrepresented in clinical trials but can experience a greater burden of disease, such as multiple sclerosis, than other racial groups in the United States. A phase 1, open-label, 2-period crossover
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2082b0b6e804a8630d6a0133a2d8e89a
https://doi.org/10.1101/2022.04.01.22272847
https://doi.org/10.1101/2022.04.01.22272847
Autor:
Kunio Nakamura, Oksana Mokliatchouk, Douglas L. Arnold, Tarek A. Yousry, Ludwig Kappos, Nancy Richert, Katherine Ayling-Rouse, Catherine Miller, Elizabeth Fisher
Publikováno v:
Frontiers in neurology. 13
ObjectiveIn the pivotal DEFINE and CONFIRM trials for dimethyl fumarate (DMF), patterns of brain volume changes were different, potentially due to low sample sizes and because MRIs were analyzed at two different reading centers. We evaluated effects
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::630d00c7001749996a5885111e81bf66
https://pubmed.ncbi.nlm.nih.gov/35370887
https://pubmed.ncbi.nlm.nih.gov/35370887
Publikováno v:
Med. 3:612-621.e3
Black/African American participants are underrepresented in clinical trials for multiple sclerosis but can experience a greater burden of disease than other racial groups in the United States. A phase 1, open-label, crossover study that demonstrated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcf10fa1ff134cb80d852ef618874177
https://doi.org/10.1016/j.medj.2022.06.006
https://doi.org/10.1016/j.medj.2022.06.006
Autor:
David Rog, Kerstin Hellwig, Christopher McGuigan, Oksana Mokliatchouk, Filipe Branco, Jennifer Lyons, Nicholas Everage
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 93:e2.107
IntroductionDimethyl fumarate (DMF) is not recommended during pregnancy and should only be used if the potential benefit justifies potential foetal risk. Given limited pregnancy data, the UK and Ireland have enrolled DMF-exposed pregnant women in an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8294ec7dd23d650a1ce17c816a263b3b
https://doi.org/10.1136/jnnp-2022-abn2.195
https://doi.org/10.1136/jnnp-2022-abn2.195